Mesoblast Limited(MESO)Earnings, Financials & Key Ratios
MESO•NASDAQ
$14.80
$1.91B mkt cap·Price updated May 7, 2026
AboutMesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.Show more
- Revenue$17M+191.4%
- EBITDA-$56M+31.9%
- Net Income-$102M-16.1%
- EPS (Diluted)-0.84+5.6%
- Gross Margin70.17%+111.8%
- EBITDA Margin-325.87%+76.6%
- Operating Margin-363.08%+74.5%
- Net Margin-593.92%+60.1%
- ROE-18.95%-5.8%
- ROIC-8.51%+26.9%
- Debt/Equity0.21-13.4%
- Interest Coverage-2.72+33.1%
MESO Key Insights
Mesoblast Limited (MESO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Sales declining 11.8% over 5 years
- ✗Shares diluted 22.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MESO Price & Volume
Mesoblast Limited (MESO) stock price & volume — 10-year historical chart
Loading chart...
MESO Growth Metrics
Mesoblast Limited (MESO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-3.18%
5 Years-11.76%
3 Years18.98%
TTM191.39%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-16.13%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM4.55%
Return on Capital
10 Years-12.2%
5 Years-12.87%
3 Years-11.57%
Last Year-9.77%
MESO Recent Earnings
Mesoblast Limited (MESO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (70%)●Beat Revenue 0/12 qtrs (0%)
Q1 2026Latest
Feb 26, 2026EPS
$0.31
Est $0.24
-31.2%
Revenue
$51M
Est $53M
-3.2%
Q4 2025
Sep 3, 2025EPS
$0.21
Est $0.37
+43.0%
Revenue
$7M
Est $31M
-77.1%
Q2 2025
Apr 30, 2025EPS
$0.21
Revenue
$7M
Est $7M
-6.2%
Q1 2025
Feb 26, 2025EPS
$0.21
Est $0.25
+16.1%
Revenue
$2M
Est $7M
-78.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.31vs $0.24-31.2% | $51Mvs $53M-3.2% |
| Q4 2025 | Sep 3, 2025 | $0.21vs $0.37+43.0% | $7Mvs $31M-77.1% |
| Q2 2025 | Apr 30, 2025 | $0.21 | $7Mvs $7M-6.2% |
| Q1 2025 | Feb 26, 2025 | $0.21vs $0.25+16.1% | $2Mvs $7M-78.9% |
Based on last 12 quarters of dataView full earnings history →
MESO Peer Comparison
Mesoblast Limited (MESO) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 MDXG | 548.21M | 3.69 | 11.53 | 19.99% | 7.88% | 12.86% | 0.09 | |
 ANIK | 202.89M | 15.14 | -19.92 | -5.91% | -9.52% | -7.74% | 0.17 | |
 RGEN | 7.13B | 126.43 | 147.01 | 16.36% | 6.73% | 2.46% | 0.33 | |
 CYTK | 9.15B | 74.29 | -11.36 | 376.56% | -7.84% | |||
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare MESO vs Peers
Mesoblast Limited (MESO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MESO Income Statement
Mesoblast Limited (MESO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.41M | 17.34M | 16.72M | 32.16M | 7.46M | 10.21M | 7.5M | 5.9M | 17.2M |
| Revenue Growth % | -94.33% | 618.95% | -3.57% | 92.3% | -76.81% | 36.95% | -26.54% | -21.32% | 191.39% |
| Cost of Goods Sold | 12.06M | 5.51M | 75.17M | 81.5M | 85.73M | 63.57M | 54.92M | 41.07M | 5.13M |
| COGS % of Revenue | 500.21% | 31.76% | 449.55% | 253.44% | 1149.83% | 622.58% | 732.2% | 695.87% | 29.83% |
| Gross Profit | -9.65M▲ 0% | 11.83M▲ 222.6% | -58.45M▼ 594.0% | -49.34M▲ 15.6% | -78.28M▼ 58.6% | -53.36M▲ 31.8% | -47.42M▲ 11.1% | -35.17M▲ 25.8% | 12.07M▲ 134.3% |
| Gross Margin % | -400.21% | 68.24% | -349.55% | -153.44% | -1049.83% | -522.58% | -632.2% | -595.87% | 70.17% |
| Gross Profit Growth % | -175.5% | 222.58% | -593.97% | 15.59% | -58.64% | 31.83% | 11.13% | 25.84% | 134.32% |
| Operating Expenses | 92.5M | 92.03M | 97.88M | 107.56M | 115.06M | 90.78M | 76.79M | 48.98M | 74.51M |
| OpEx % of Revenue | 3834.87% | 530.71% | 585.36% | 334.5% | 1543.17% | 889.09% | 1023.73% | 829.87% | 433.25% |
| Selling, General & Admin | 35.07M | 27.41M | 36.98M | 50.92M | 63.59M | 57.97M | 53.11M | 23.63M | 39.31M |
| SG&A % of Revenue | 1454.06% | 158.09% | 221.16% | 158.35% | 852.82% | 567.69% | 708% | 400.31% | 228.57% |
| Research & Development | 58.91M | 65.93M | 59.81M | 56.19M | 53.01M | 32.81M | 27.19M | 25.35M | 34.81M |
| R&D % of Revenue | 2442.54% | 380.18% | 357.7% | 174.74% | 711% | 321.37% | 362.47% | 429.57% | 202.39% |
| Other Operating Expenses | 10.53M | -1.31M | 15.48M | 25.23M | 32.65M | 30.76M | 0 | 0 | 395K |
| Operating Income | -90.04M▲ 0% | -77.34M▲ 14.1% | -80.2M▼ 3.7% | -74.87M▲ 6.6% | -109.1M▼ 45.7% | -80.57M▲ 26.1% | -69.29M▲ 14.0% | -84.15M▼ 21.4% | -62.44M▲ 25.8% |
| Operating Margin % | -3733.08% | -445.99% | -479.62% | -232.84% | -1463.2% | -789.09% | -923.73% | -1425.74% | -363.08% |
| Operating Income Growth % | -61.11% | 14.11% | -3.7% | 6.65% | -45.71% | 26.14% | 14.01% | -21.44% | 25.79% |
| EBITDA | -86.98M | -74.69M | -78.06M | -71.2M | -104.83M | -76.19M | -65.18M | -82.25M | -56.04M |
| EBITDA Margin % | -3606.34% | -430.71% | -466.83% | -221.44% | -1406.01% | -746.2% | -868.98% | -1393.63% | -325.87% |
| EBITDA Growth % | -62% | 14.14% | -4.52% | 8.79% | -47.23% | 27.32% | 14.45% | -26.19% | 31.86% |
| D&A (Non-Cash Add-back) | 3.06M | 2.65M | 2.14M | 3.67M | 4.26M | 4.38M | 4.11M | 1.9M | 6.4M |
| EBIT | -90.22M | -64.15M | -86.67M | -72.64M | -88.92M | -74.3M | -62.66M | -57.97M | -80.06M |
| Net Interest Income | 468K | -1.46M | -10.98M | -14.17M | -10.71M | -17.29M | -18.61M | -18.83M | -19.38M |
| Interest Income | 468K | 366K | 719K | 542K | 0 | 0 | 831K | 1.82M | 3.55M |
| Interest Expense | 0 | 1.83M | 11.7M | 14.72M | 10.71M | 17.29M | 19.44M | 20.66M | 22.93M |
| Other Income/Expense | -173K | 9.24M | -18.34M | -12.48M | 9.47M | -10.48M | -12.81M | -4M | -39.37M |
| Pretax Income | -90.22M▲ 0% | -65.98M▲ 26.9% | -98.75M▼ 49.7% | -87.36M▲ 11.5% | -99.63M▼ 14.1% | -91.59M▲ 8.1% | -82.1M▲ 10.4% | -88.15M▼ 7.4% | -101.81M▼ 15.5% |
| Pretax Margin % | -3740.26% | -380.47% | -590.56% | -271.66% | -1336.24% | -896.93% | -1094.53% | -1493.51% | -592% |
| Income Tax | -13.4M | -30.69M | -8.96M | -9.41M | -819K | -239K | -212K | -191K | 330K |
| Effective Tax Rate % | 14.85% | 46.51% | 9.07% | 10.78% | 0.82% | 0.26% | 0.26% | 0.22% | -0.32% |
| Net Income | -76.81M▲ 0% | -35.29M▲ 54.1% | -89.8M▼ 154.5% | -77.94M▲ 13.2% | -98.81M▼ 26.8% | -91.35M▲ 7.6% | -81.89M▲ 10.4% | -87.96M▼ 7.4% | -102.14M▼ 16.1% |
| Net Margin % | -3184.7% | -203.51% | -537.01% | -242.38% | -1325.25% | -894.59% | -1091.71% | -1490.27% | -593.92% |
| Net Income Growth % | -1761.28% | 54.06% | -154.46% | 13.21% | -26.78% | 7.55% | 10.35% | -7.41% | -16.13% |
| Net Income (Continuing) | -76.81M | -35.29M | -89.8M | -77.94M | -98.81M | -91.35M | -81.89M | -87.96M | -102.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.40▲ 0% | -0.76▲ 45.7% | -1.80▼ 136.8% | -1.50▲ 16.7% | -1.60▼ 6.7% | -1.30▲ 18.8% | -0.98▲ 24.6% | -0.89▲ 9.2% | -0.84▲ 5.6% |
| EPS Growth % | -1718.18% | 45.71% | -136.84% | 16.67% | -6.67% | 18.75% | 24.62% | 9.18% | 5.62% |
| EPS (Basic) | -1.40 | -0.76 | -1.80 | -1.50 | -1.60 | -1.30 | -0.98 | -0.89 | -0.84 |
| Diluted Shares Outstanding | 53.77M | 46.57M | 49.44M | 52.88M | 60.51M | 68.29M | 83.93M | 98.67M | 120.78M |
| Basic Shares Outstanding | 53.77M | 46.56M | 49.44M | 52.88M | 60.51M | 68.27M | 83.77M | 98.67M | 120.78M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
MESO Balance Sheet
Mesoblast Limited (MESO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 63.61M | 101.07M | 62.52M | 136.55M | 148.23M | 69.84M | 81.66M | 86.46M | 204.35M |
| Cash & Short-Term Investments | 45.76M | 37.76M | 50.43M | 129.33M | 136.88M | 60.03M | 70.92M | 62.56M | 161.16M |
| Cash Only | 45.76M | 37.76M | 50.43M | 129.33M | 136.88M | 60.03M | 70.92M | 62.56M | 161.16M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.29M | 46.28M | 1.74M | 1.32M | 4.59M | 4.4M | 7M | 20.95M | 14.87M |
| Days Sales Outstanding | 195.51 | 974.03 | 38 | 15.01 | 224.7 | 157.39 | 340.52 | 1.3K | 315.51 |
| Inventory | 13.86M | -43.74M | -250K | -252K | -252K | 0 | 0 | 0 | 22.25M |
| Days Inventory Outstanding | 419.15 | - | - | - | - | - | - | - | 1.58K |
| Other Current Assets | 38.04M | 542K | 421K | 412K | 451K | 413K | 398K | 397K | 393K |
| Total Non-Current Assets | 592.08M | 591.37M | 589.59M | 597.05M | 596.49M | 592.3M | 587.76M | 582.69M | 580.33M |
| Property, Plant & Equipment | 1.81M | 1.08M | 826K | 10.27M | 12.14M | 9.96M | 6.49M | 3.84M | 5.82M |
| Fixed Asset Turnover | 1.33x | 16.00x | 20.24x | 3.13x | 0.61x | 1.02x | 1.16x | 1.54x | 2.95x |
| Goodwill | 134.45M | 134.45M | 134.45M | 134.45M | 134.45M | 134.45M | 134.45M | 134.45M | 134.45M |
| Intangible Assets | 451.9M | 450.15M | 448.67M | 447.15M | 446.09M | 444.2M | 442.73M | 441.28M | 437.37M |
| Long-Term Investments | 2M | 2.32M | 2.32M | 1.87M | 2.08M | 1.76M | 1.76M | 1.01M | 1.39M |
| Other Non-Current Assets | 1.92M | 3.36M | 3.32M | 3.31M | 1.72M | 1.68M | 481K | 2.1M | 1.3M |
| Total Assets | 655.69M▲ 0% | 692.44M▲ 5.6% | 652.12M▼ 5.8% | 733.6M▲ 12.5% | 744.72M▲ 1.5% | 662.14M▼ 11.1% | 669.41M▲ 1.1% | 669.15M▼ 0.0% | 784.68M▲ 17.3% |
| Asset Turnover | 0.00x | 0.03x | 0.03x | 0.04x | 0.01x | 0.02x | 0.01x | 0.01x | 0.02x |
| Asset Growth % | -4.14% | 5.61% | -5.82% | 12.5% | 1.52% | -11.09% | 1.1% | -0.04% | 17.27% |
| Total Current Liabilities | 36.67M | 24M | 44.33M | 90.14M | 94.27M | 51.37M | 41.98M | 73.24M | 102.63M |
| Accounts Payable | 21.8M | 18.92M | 13.06M | 24.97M | 19.6M | 23.08M | 20.14M | 7.07M | 19.08M |
| Days Payables Outstanding | 659.66 | 1.25K | 63.41 | 111.84 | 83.44 | 132.51 | 133.88 | 62.83 | 1.36K |
| Short-Term Debt | 0 | 0 | 14.01M | 32.45M | 53.2M | 5.02M | 5.95M | 13.86M | 54.16M |
| Deferred Revenue (Current) | 0 | 0 | -14.01M | -35.97M | -55.97M | 17.91M | 6.4M | 0 | 0 |
| Other Current Liabilities | 14.87M | 5.08M | 17.26M | 29.2M | 18.71M | 2.19M | 5.43M | 49.69M | 26.71M |
| Current Ratio | 1.73x | 4.21x | 1.41x | 1.51x | 1.57x | 1.36x | 1.95x | 1.18x | 1.99x |
| Quick Ratio | 1.36x | 6.03x | 1.42x | 1.52x | 1.57x | 1.36x | 1.95x | 1.18x | 1.77x |
| Cash Conversion Cycle | -45 | - | - | - | - | - | - | - | 540.63 |
| Total Non-Current Liabilities | 102.25M | 122.43M | 126.73M | 94.13M | 69.05M | 113.72M | 125.59M | 115.56M | 84.61M |
| Long-Term Debt | 0 | 59.4M | 67.28M | 57.02M | 41.05M | 91.62M | 102.81M | 100.48M | 67.74M |
| Capital Lease Obligations | 0 | 0 | 0 | 6.32M | 8.48M | 7.08M | 3.67M | 1.95M | 3.58M |
| Deferred Tax Liabilities | 49.29M | 20.08M | 11.12M | 730K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 52.96M | 63.03M | 48.33M | 30.06M | 19.52M | 15.02M | 19.11M | 13.12M | 13.29M |
| Total Liabilities | 138.92M | 146.44M | 171.06M | 184.28M | 163.32M | 165.1M | 167.58M | 188.8M | 187.24M |
| Total Debt | 0 | 59.4M | 81.29M | 99.31M | 105.5M | 106.91M | 116.5M | 118.92M | 128.16M |
| Net Debt | -45.76M | 21.63M | 30.86M | -30.01M | -31.39M | 46.87M | 45.58M | 56.36M | -33M |
| Debt / Equity | - | 0.11x | 0.17x | 0.18x | 0.18x | 0.22x | 0.23x | 0.25x | 0.21x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -42.28x | -6.85x | -5.09x | -10.18x | -4.66x | -3.56x | -4.07x | -2.72x |
| Total Equity | 516.77M▲ 0% | 546.01M▲ 5.7% | 481.05M▼ 11.9% | 549.33M▲ 14.2% | 581.4M▲ 5.8% | 497.04M▼ 14.5% | 501.84M▲ 1.0% | 480.36M▼ 4.3% | 597.44M▲ 24.4% |
| Equity Growth % | -2.16% | 5.66% | -11.9% | 14.19% | 5.84% | -14.51% | 0.96% | -4.28% | 24.38% |
| Book Value per Share | 9.61 | 11.72 | 9.73 | 10.39 | 9.61 | 7.28 | 5.98 | 4.87 | 4.95 |
| Total Shareholders' Equity | 516.77M | 546.01M | 481.05M | 549.33M | 581.4M | 497.04M | 501.84M | 480.36M | 597.44M |
| Common Stock | 830.42M | 889.48M | 910.4M | 1.05B | 1.16B | 1.17B | 1.25B | 1.31B | 1.51B |
| Retained Earnings | -344.9M | -380.19M | -469.99M | -548.76M | -647.57M | -738.92M | -820.8M | -908.76M | -1.01B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 31.24M | 36.72M | 40.64M | 46.63M | 65.81M | 70.65M | 73.52M | 78.3M | 99.5M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MESO Cash Flow Statement
Mesoblast Limited (MESO) cash flow — operating, investing & free cash flow history
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -95.47M | -75.01M | -57.79M | -56.37M | -106.68M | -65.78M | -63.27M | -48.46M | -49.95M |
| Operating CF Margin % | -3958.17% | -432.57% | -345.59% | -175.29% | -1430.81% | -644.23% | -843.47% | -821.04% | -290.46% |
| Operating CF Growth % | -8.49% | 21.43% | 22.96% | 2.47% | -89.27% | 38.34% | 3.82% | 23.41% | -3.09% |
| Net Income | -76.81M | -35.29M | -89.8M | -77.94M | -98.81M | -91.35M | -81.89M | -87.96M | -102.14M |
| Depreciation & Amortization | 3.06M | 2.65M | 2.14M | 3.67M | 4.26M | 4.38M | 4.11M | 4.67M | 6.4M |
| Stock-Based Compensation | 5.28M | 6.2M | 4.37M | 7.52M | 12.51M | 5.54M | 3.65M | 5.87M | 22.09M |
| Deferred Taxes | -13.4M | -30.66M | -8.96M | -9.41M | -819K | -235K | -212K | -191K | 330K |
| Other Non-Cash Items | 168K | -8.98M | 14.02M | 6.51M | -15.41M | 11.02M | 13.54M | 31.78M | 26.41M |
| Working Capital Changes | -13.76M | -8.93M | 20.44M | 13.29M | -8.42M | 4.87M | -2.47M | -2.63M | -3.04M |
| Change in Receivables | -859K | -6.09M | 4.97M | 890K | -1.74M | 140K | -118K | -15.47M | 6.29M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 826K |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 142K | -1.15M | -1M | -3.27M | -1.65M | -232K | -194K | -97K | 120K |
| Capital Expenditures | -311K | -201K | -279K | -2.25M | -1.65M | -232K | -314K | -271K | -680K |
| CapEx % of Revenue | 12.89% | 1.16% | 1.67% | 6.98% | 22.09% | 2.27% | 4.19% | 4.59% | 3.95% |
| Acquisitions | 0 | -952K | -721K | -1.03M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 453K | -952K | -721K | -1.03M | 0 | -75K | 120K | -60K | 559K |
| Cash from Financing | 60.01M | 68.61M | 71.61M | 137.04M | 114.47M | -9.87M | 74.5M | 40.25M | 147.34M |
| Debt Issued (Net) | 0 | 31.7M | 43.57M | -1.63M | -2.93M | -6.33M | -2.66M | -13.52M | -9.77M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 209K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -1.93M | -3.66M | -2.22M | -6.28M | 5.2M | -3.75M | -11.48M | -11.63M | -4.1M |
| Net Change in Cash | -35.18M▲ 0% | -8M▲ 77.3% | 12.66M▲ 258.3% | 78.9M▲ 523.1% | 7.55M▼ 90.4% | -76.43M▼ 1112.0% | 10.87M▲ 114.2% | -8.36M▼ 176.9% | 98.59M▲ 1279.6% |
| Free Cash Flow | -95.78M▲ 0% | -75.21M▲ 21.5% | -58.07M▲ 22.8% | -58.61M▼ 0.9% | -108.33M▼ 84.8% | -66.01M▲ 39.1% | -63.58M▲ 3.7% | -48.79M▲ 23.3% | -50.68M▼ 3.9% |
| FCF Margin % | -3971.06% | -433.73% | -347.26% | -182.27% | -1452.9% | -646.5% | -847.66% | -826.65% | -294.71% |
| FCF Growth % | -7.72% | 21.47% | 22.79% | -0.93% | -84.83% | 39.06% | 3.68% | 23.27% | -3.88% |
| FCF per Share | -1.78 | -1.62 | -1.17 | -1.11 | -1.79 | -0.97 | -0.76 | -0.49 | -0.42 |
| FCF Conversion (FCF/Net Income) | 1.24x | 2.13x | 0.64x | 0.72x | 1.08x | 0.72x | 0.77x | 0.55x | 0.49x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MESO Key Ratios
Mesoblast Limited (MESO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -0.73% | -14.7% | -6.64% | -17.49% | -15.13% | -17.48% | -16.94% | -16.4% | -17.91% | -18.95% |
| Return on Invested Capital (ROIC) | -7.7% | -13.82% | -11.17% | -11.14% | -10.89% | -15.3% | -11.05% | -9.52% | -11.64% | -8.51% |
| Gross Margin | 30.05% | -400.21% | 68.24% | -349.55% | -153.44% | -1049.83% | -522.58% | -632.2% | -595.87% | 70.17% |
| Net Margin | -9.7% | -3184.7% | -203.51% | -537.01% | -242.38% | -1325.25% | -894.59% | -1091.71% | -1490.27% | -593.92% |
| Debt / Equity | - | - | 0.11x | 0.17x | 0.18x | 0.18x | 0.22x | 0.23x | 0.25x | 0.21x |
| Interest Coverage | - | - | -42.28x | -6.85x | -5.09x | -10.18x | -4.66x | -3.56x | -4.07x | -2.72x |
| FCF Conversion | 21.32x | 1.24x | 2.13x | 0.64x | 0.72x | 1.08x | 0.72x | 0.77x | 0.55x | 0.49x |
| Revenue Growth | 79.16% | -94.33% | 618.95% | -3.57% | 92.3% | -76.81% | 36.95% | -26.54% | -21.32% | 191.39% |
MESO Frequently Asked Questions
Mesoblast Limited (MESO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Mesoblast Limited (MESO) reported $17.2M in revenue for fiscal year 2025. This represents a 3320% increase from $0.5M in 2005.
Mesoblast Limited (MESO) grew revenue by 191.4% over the past year. This is strong growth.
Mesoblast Limited (MESO) reported a net loss of $102.1M for fiscal year 2025.
Dividend & Returns
Mesoblast Limited (MESO) has a return on equity (ROE) of -19.0%. Negative ROE indicates the company is unprofitable.
Mesoblast Limited (MESO) had negative free cash flow of $48.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More MESO
Mesoblast Limited (MESO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates